eritoran

Also Known As:

3-O-decyl-2-deoxy-6-O-(2-deoxy-3-O-(3-methoxydecyl)-6-O-methyl-2-((1-oxo-11-octadecenyl)amino)-4-O-phosphonoglucopyranosyl)-2-((1,3-dioxotetradecyl)amino)-1-(dihydroxy phosphate)glucopyranose

Networked: 45 relevant articles (10 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023

Experts

1.	Rossignol, Daniel P: 6 articles (05/2013 - 09/2004)
2.	Lynn, Melvyn: 6 articles (03/2013 - 09/2004)
3.	LaRosa, Steven P: 4 articles (08/2016 - 05/2011)
4.	Gusovsky, Fabian: 3 articles (01/2019 - 05/2013)
5.	Opal, Steven M: 3 articles (03/2013 - 01/2010)
6.	Tidswell, Mark: 3 articles (03/2013 - 01/2010)
7.	Wong, Nancy: 3 articles (12/2008 - 09/2004)
8.	Blanco, Jorge C G: 2 articles (01/2019 - 05/2013)
9.	Lai, Wendy: 2 articles (01/2019 - 05/2013)
10.	Shirey, Kari Ann: 2 articles (01/2019 - 05/2013)

Related Diseases

1.	Sepsis (Septicemia) 02/29/2008 - "Evidence from a single phase II trial of eritoran usage in sepsis suggests that it is a safe and effective therapeutic option for patients with sepsis, and is especially beneficial for patients at high risk of mortality. " 07/01/2012 - "In January 2011, it was announced that the worldwide phase 3 randomized trial of a novel anti-Toll-like receptor-4 compound, eritoran tetrasodium, had failed to demonstrate an improvement in the mortality of patients with severe sepsis. " 01/01/2014 - "Although eritoran showed positive results in phase I and phase II clinical trials of severe sepsis, a phase III clinical study for severe sepsis has failed. " 10/01/2011 - "This analysis aimed to assess the efficacy of eritoran based on severity of illness and similar effects in other recent sepsis trials. " 11/20/2021 - "We critically analyze preclinical investigations into the role of TLRs in animal sepsis, the complexity of targeting TLRs for sepsis intervention, and the disappointing clinical trials of the TLR4 antagonist eritoran. "
2.	Infections 01/01/2016 - "If treatment is initiated 3 h before PR8 infection and continued daily for 4 days, Eritoran failed to protect WT and TLR4(-/-) mice, implying that Eritoran must block a virus-induced, non-TLR4 signal that is required for protection. " 01/01/2017 - "Hence, these studies are the first to demonstrate the role of TLR4 in the pathogenesis of EBOV disease and indicate that eritoran is a prime candidate for further evaluation as a clinically viable therapeutic intervention strategy for EBOV and MARV infections.IMPORTANCE A hallmark of bacterial sepsis is the uncontrolled activation of the TLR4 pathway, which is the primary cause of the pathological features associated with this disease. " 01/01/2019 - "Our findings support the conclusion that selective suppression of CXCL1/CXCL2 represents an IFN-β-mediated "training" of the macrophage transcriptional response to TLR2 agonists and that blocking of TLR4 therapeutically with Eritoran after influenza virus infection reverses this suppression by blunting influenza-induced IFN-β." 01/01/2017 - "Here, we show that eritoran effectively promotes survival of mice of filovirus infection, as 70% and 90% of mice receiving daily eritoran treatment survived lethal EBOV and MARV infections, respectively. " 01/01/2017 - "Considering the importance of TLR4 signaling in bacterial sepsis and the remarkable pathological similarities associated with infections caused by filoviruses Ebola virus (EBOV) and Marburg virus (MARV), we assessed the ability of eritoran, a TLR4 antagonist, to protect mice against these viruses. "
3.	Reperfusion Injury 06/01/2010 - "Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury." 07/04/2006 - "Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury." 03/13/2015 - "Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling."
4.	Wounds and Injuries (Trauma) 10/01/2013 - "Eritoran may represent a promising therapeutic for trauma patients to prevent multiple organ failure." 10/01/2013 - "Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma."
5.	Pneumonia (Pneumonitis) 01/01/2022 - "In order to evaluate therapeutic efficacy by eritoran, we are participating in the international network REMAP-CAP-COVID (Randomized, Embedded, Multi-factorial, Adaptive Platform-Community Acquired Pneumonia COVID) which aims for novel coronavirus medicine development through drug repurposing, and began an international collaborative clinical trial in October 2020 which is designated for confirmed novel coronavirus patients who are hospitalized and are in a progressing disease state. " 01/01/2022 - "It is hoped that through suppressing the most upstream TLR4 activity which controls production of multiple cytokines by eritoran, the cytokine storm in patients can be suppressed and pneumonia can thus be prevented from becoming severe. "

Related Drugs and Biologics

1.	E5564
2.	Toll-Like Receptor 4
3.	Anti-Inflammatory Agents (Anti-Inflammatories)
4.	Lipid A
5.	Antiviral Agents (Antivirals)
6.	Oseltamivir (Tamiflu)
7.	Lipopolysaccharides
8.	Interleukin-1 Receptors (Interleukin 1 Receptor)
9.	Therapeutic Uses
10.	Antithrombins

Related Therapies and Procedures

1.	Therapeutics
2.	Catheters
3.	Resuscitation
4.	Subcutaneous Injections